Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of Alberta

$50,000.00

Scalable Synthesis of Antiviral Compounds (COVID-19)_x000d_

FY 2020-21

Summary
The COVID-19 pandemic has relatively quickly become a worldwide threat to human health and the economy. Because of the long timeline for vaccine development, and the very real possibility that any vaccine developed may confer limited immunity, other approaches for containing the disease are needed. Here we propose a program to develop efficient synthetic routes to two novel small molecule compounds that have been shown to inhibit infectivity of SARS-CoV-2 in cell culture. These compounds were originally prepared in milligram quantities, using synthetic routes that were unoptimized and not suitable for larger-scale synthesis. For this Alliance Grant project, we will reexamine the synthetic routes to two target compounds 3 and 5 (see proposal). There are several problems with the existing routes, including expensive reagents that need to be used in excess, and very low yields for several of the steps. We will attempt to optimize the low-yielding steps, and explore alternative starting materials that will not require the expensive coupling reagent EDCI. We will also attempt to develop a robust purification protocol for both target compounds that does not require large-scale chromatography. Throughout the course of the project, trainees in the West group will meet with scientists at the partner organization, IntelliSyn RD. These chemists have extensive experience with scale-up problems and route challenges that could negatively impact eventual GMP manufacture, if these compounds are selected for further development. This collaboration will offer a strong training opportunity for trainees involved, exposing them to the kinds of R&D problems that are frequently encountered in a pharmaceutical setting, which could serve them well in future career choices. It also enhances Canada's biopharmaceutical sector by establishing a strong academic-industrial partnership and providing a growing company with the opportunity to partner in moving forward a promising new technology.
Program
Alliance Grants
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
554611-2020
Name nom
West, Frederick
Department département
Chemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Scalable Synthesis of Antiviral Compounds (COVID-19)_x000d_
Keyword
NSERC
Application summary
The COVID-19 pandemic has relatively quickly become a worldwide threat to human health and the economy. Because of the long timeline for vaccine development, and the very real possibility that any vaccine developed may confer limited immunity, other approaches for containing the disease are needed. Here we propose a program to develop efficient synthetic routes to two novel small molecule compounds that have been shown to inhibit infectivity of SARS-CoV-2 in cell culture. These compounds were originally prepared in milligram quantities, using synthetic routes that were unoptimized and not suitable for larger-scale synthesis. For this Alliance Grant project, we will reexamine the synthetic routes to two target compounds 3 and 5 (see proposal). There are several problems with the existing routes, including expensive reagents that need to be used in excess, and very low yields for several of the steps. We will attempt to optimize the low-yielding steps, and explore alternative starting materials that will not require the expensive coupling reagent EDCI. We will also attempt to develop a robust purification protocol for both target compounds that does not require large-scale chromatography. Throughout the course of the project, trainees in the West group will meet with scientists at the partner organization, IntelliSyn RD. These chemists have extensive experience with scale-up problems and route challenges that could negatively impact eventual GMP manufacture, if these compounds are selected for further development. This collaboration will offer a strong training opportunity for trainees involved, exposing them to the kinds of R&D problems that are frequently encountered in a pharmaceutical setting, which could serve them well in future career choices. It also enhances Canada's biopharmaceutical sector by establishing a strong academic-industrial partnership and providing a growing company with the opportunity to partner in moving forward a promising new technology.